Fundraising Fox
Aktis Oncology
NASDAQ: AKTSBoston, US · Founded 2020 · Delaware corporation · 102 employees on LinkedIn · 20 known investors
Find your way into Aktis Oncology
Sign up to see every warm intro you have to Aktis Oncology
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Aktis Oncology team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Aktis Oncology discovers and develops targeted radiopharmaceuticals for treating solid tumors. The company serves oncology patients and healthcare providers in the cancer care sector.
Founders & leadership
Aktis Oncology was founded in 2020 by Todd Foley and Patrick Baeuerle.
Board
Investors · 20
How we know: a16z's portfolio · Not right? Tell us
How we know: the S-1 prospectus · board seat on SEC Form D · labiotech.eu · Not right? Tell us
How we know: MPM BioImpact's portfolio page · the S-1 prospectus · a partner's Signal profile · labiotech.eu · Not right? Tell us
How we know: MRL Ventures Fund's portfolio page · labiotech.eu · Not right? Tell us
How we know: Pappas Capital's portfolio page · Not right? Tell us
How we know: RA Capital's portfolio page · biopharmadive.com · Not right? Tell us
How we know: Vida Ventures's portfolio page · board seat on SEC Form D · labiotech.eu · the VCSheet dataset · Not right? Tell us
Also in the syndicate · 8
Funding
SEC filings, press & company announcements$175M disclosed across 1 of 4 rounds · 2021–2026
- Undisclosed amountseries A extensionAug 2022
ArrowMark Partners, Bristol Myers Squibb, Cowen Healthcare Investments, EcoR1 Capital, Mirae Asset Venture, MPM Capital, MRL Ventures Fund, Novartis, Octagon Capital, Pappas Capital, TCG Crossover, Timefolio Capital, Vida Ventures
Source ↗ - Undisclosed amountSeries AMar 2021Source ↗
▶$175MraisedOct 2024 · 39 investors · BiotechnologyRule 506(b)
- Helen S. KimDirector
- Shulamit Ron-BiggerExecutive Officer
- Ken HerrmannDirector
- Lloyd SegalDirector
- Oleg NodelmanDirector
- Andrew LevinDirector
- Matthew RodenExecutive Officer, Director
- Todd FoleyDirector
- Offering amount
- $175M
- Amount sold
- $175M
- First sale
- Sep 2024
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed eventsSource: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Founder mafia
2 people who came through Aktis Oncology went on to found or lead other companies.
Related companies · 3
Companies working in the same space as Aktis Oncology.
In the news
Frequently asked questions
- What does Aktis Oncology do?
- Aktis Oncology discovers and develops targeted radiopharmaceuticals for treating solid tumors. The company serves oncology patients and healthcare providers in the cancer care sector.
- Who founded Aktis Oncology?
- Aktis Oncology was founded by Todd Foley, Patrick Baeuerle in 2020.
- Who are Aktis Oncology's investors?
- Aktis Oncology's investors include Andreessen Horowitz, EcoR1 Capital, MPM BioImpact, MRL Ventures Fund, Pappas Capital, RA Capital, TCG Crossover, Vida Ventures and 4 more.
- How much funding has Aktis Oncology raised?
- Aktis Oncology has disclosed $175M raised across 1 of its 4 known rounds.
- Where is Aktis Oncology headquartered?
- Aktis Oncology is headquartered in Boston, US.